The 14-gene signature (11 cancer-related genes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A and three reference genes ESD, TBP, and YAP1) predicts survival in resected nonsquamous, non-small-cell lung cancer [4], identifies patients at high risk of mortality despite small, node-negative lung tumors [5], improves identification of patients at risk for recurrence in early-stage none small cell lung cancer [6], and predicts benefit from adjuvant chemotherapy for very early stage NSCLC and is superior over current NCCN criteria at identifying high-risk patients [7]. The gene discussed is LCK; the disease is cancer.